#USA #Providence #Nabsys #LINE-1 #OhmX

Discovering the Future of Genetic Research

In a significant advance for genetic research, Nabsys 2.0, LLC, a trailblazer in electronic genome mapping (EGM), has unveiled groundbreaking findings at the Advances in Genome Biology and Technology (AGBT) 2026 conference. The presentation highlighted their innovative poster titled "Direct genome-scale mapping of endonuclease activity of the human LINE-1 ORF2p endonuclease." This poster features compelling data produced by a research team led by Dr. Martin Taylor from Brown University.

The Importance of EGM Technology

Electronic genome mapping offers scientists a powerful tool to understand the genetic landscape of complex organisms. By allowing researchers to identify DNA nicking events across long DNA molecules, EGM addresses longstanding challenges in pinpointing where endonuclease-induced alterations occur. This capability is vital for studies investigating the implications of such modifications on genetic integrity, particularly within intricate DNA mixtures.

The data presented by the Nabsys and Dr. Taylor's team illustrate how EGM can be utilized to examine the nucleotide locations affected by the LINE-1 ORF2p endonuclease. LINE-1, an autonomous retrotransposon, has a unique ability to propagate itself in the human genome, accounting for nearly a third of its composition. With around 5% of humans possessing LINE-1 insertions absent from their parents, the understanding of this transposon is critical.

LINE-1 and Its Genomic Influence

Recent research underscores the dual role of LINE-1 activity: on one hand, it facilitates genomic diversity and evolution; on the other, it poses risks for genomic instability, particularly associated with various diseases, including cancer and neurodegenerative disorders. The ability of the LINE-1 ORF2p to cause DNA breaks introduces complexities that can lead to insertions and structural genomic shifts, a phenomenon recognized as a factor in cancer progression.

Dr. Taylor elaborates, stating, "Our comprehension of how LINE-1 endonucleases interact with genomic sequences remains relatively incomplete. Gaining insights into this enzymatic activity is paramount for elucidating the damaging effects LINE-1 can have on DNA. The technological advancements represented by EGM position us magnificently to map this activity across the genome like never before."

The Mechanics of EGM

In preparation for the experiment, DNA samples treated with the LINE-1 ORF2p endonuclease were labeled using the OhmX Velocity Optimized Label and Tagging™ (VOLT) Whole Genome Kit. By analyzing these labeled samples on the OhmX™ Platform, researchers successfully identified and charted the locations of endonuclease-induced nicks. This allowed them to assess how the endonuclease’s activity varied in a concentration-dependent manner, providing richer insights into its function.

Barrett Bready, MD, the founder and CEO of Nabsys, commented on the broader implications of this research. "LINE-1 activity is implicated in the pathogenesis of common diseases like cancer through the induction of inflammation and DNA damage. The collaboration with Dr. Taylor's team has been fruitful, and we anticipate that EGM will serve as a significant resource for measuring genome-wide DNA modifications, impacting the discovery and development of cell and gene therapies."

Looking Forward

Nabsys is committed to further advancing genomic research through continuous innovation. By focusing on the accessibility of its electronic genome mapping technology, the organization aims to democratize high-resolution genomic insights, paving the way for developments in cytogenetics, molecular genetics, and beyond. Since its inception in 2005, Nabsys has established itself as a leading force in genetic technology, based in Providence, Rhode Island. Their work continues to redefine the possibilities of genetic research and therapy.

For more information on Nabsys and its ongoing projects, visit www.nabsys.com.